title: Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy.
abstract: We have previous found a positive correlation between post-therapy TCR repertoire normalization and remission of colorectal cancer (CRC) patients following fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab or Rh-endostatin therapy. To further define the TCR repertoire diversity changes following treatment in CRC patients, and confirm its potential prognostic value, the present study extended the sample size of follow-up and used an alternative therapy regime to investigate changes of TCR repertoires following Erbitux plus FOLFIRI therapy. Inclusion and exclusion criteria have been established to screen out 26 patients to receive Erbitux plus FOLFIRI therapy. Efficacy and toxicity assessment have been made for them after 3 months' treatment as well as the TCR repertoire diversity has been determined. A CDR3 complex scoring system was used to quantify the diversity of TCR repertoire. The results showing that the diversity of CD4(+) T cells in PR group was significantly higher than that of SD and PD groups, and the difference was enlargement after treatment. The diversity of CD8(+) T cells in PR group has no difference before and after treatment, but significant decrease in SD and PD group after treatment. In conclusion, analysis the diversity of T cell repertoire has an important prognosis value for CRC patients.
authors.affiliation: Institute of Molecular Immunology, School of Biotechnology, Southern Medical University Guangzhou 510515, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Luo
authors.affiliation: Institute of Molecular Immunology, School of Biotechnology, Southern Medical University Guangzhou 510515, China.
authors.forename: Wen-Ting
authors.initials: WT
authors.lastname: He
authors.affiliation: Institute of Molecular Immunology, School of Biotechnology, Southern Medical University Guangzhou 510515, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Wen
authors.affiliation: Cancer Research Institute, Foshan First People's Hospital Foshan, Guangdong 528000, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Chen
authors.affiliation: Cancer Research Institute, Foshan First People's Hospital Foshan, Guangdong 528000, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.affiliation: Cancer Research Institute, Foshan First People's Hospital Foshan, Guangdong 528000, China.
authors.forename: Xiang-Ping
authors.initials: XP
authors.lastname: Chen
authors.affiliation: Institute of Molecular Immunology, School of Biotechnology, Southern Medical University Guangzhou 510515, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
keywords: Colorectal cancer (CRC); Erbitux; T cell receptor (TCR); TCR repertoire; complementarity determining region 3 (CDR3)